viewSilence Therapeutics PLC

Silence Therapeutics appoints industry veteran to oversee manufacturing

"It is exciting to be involved in the development of products which have the potential to positively impact the lives of patients with serious diseases," said Wittendorff

Silence Therapeutics PLC - Silence Therapeutics appoints industry veteran to oversee manufacturing
"Silence has an impressive portfolio of assets in the siRNA field," Wittendorff said

Pharmaceutical products development veteran Jørgen Wittendorff has been appointed as head of manufacturing at Silence Therapeutics PLC (LON:SLN).

He will be responsible for the process development and manufacturing of siRNA (silencing ribonucleic acid) therapeutic products for clinical trials and, ultimately, commercial use.

Wittendorff has more than 25 years of experience in the industry, having previously been a senior director at CMC manufacturing and product supply at Ablynx and also having held senior positions at Ferring Pharmaceuticals and Novo Nordisk.

“Jørgen's extensive experience in complex manufacturing from Ablynx will be a significant contribution to Silence,” said David Horn Solomon, the chief executive officer of Silence.

“In his new role, Jørgen will be able to critically contribute to the manufacturing efforts to progress Silence's three significant sets of assets in gene silencing siRNA: SLN124, for the treatment of iron overload disorders, SL360, for the treatment of cardiovascular disease, and SL500 with partner Mallinckrodt Pharmaceuticals, for the treatment of complement-mediated disorders," he added.


Quick facts: Silence Therapeutics PLC

Price: 463 GBX

Market: AIM
Market Cap: £383.49 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Silence Therapeutics PLC named herein, including the promotion by the Company of Silence Therapeutics PLC in any Content on the Site, the...


Silence Therapeutics 'in a hot space with few competitors'

Silence Therapeutics' (LON:SLN) executive chair Annalisa Jenkins sat down with Proactive's Andrew Scott to discuss her strategy for taking the drug developer forward and the 'exciting opportunities' in the RNAi space. On what attracted Jenkins to join Silence, she says: ''The opportunity...

on 12/6/18

2 min read